ISNTD d3 2021
Drug discovery, development & diagnostics for neglected tropical diseases
Online conference
24-25th February 2021
#ISNTDd3
#beatNTDs
Introduction
ISNTD d³ 2021 addresses the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development, vaccine R&D and uptake, and diagnostics and surveillance opportunities.
This year, against the backdrop of the recently launched WHO NTD Roadmap and the shock of the COVID19 pandemic, ISNTD d³ will focus on the shifts, gaps and future needs of drug discovery, treatments and diagnostics in context of global health as well as broader challenges.
Presentations & panel discussions will run on both days, and partnership meetings can be arranged throughout the day.
Please contact for further details including speaking & attending and to become a conference sponsor.
Programme
DRUG DISCOVERY & DEVELOPMENT
ISNTD d3 2021: DAY 1
24 FEB 2021
9.00-10.00 UTC
Rethinking financial incentives for drugs and diagnostics for Neglected Tropical Diseases
Andrew Jack (Financial Times)
Panel chair
Dr Hayato Urabe (Senior Director, Investment Strategy, Portfolio Development & Innovations, GHIT Fund)
Dr Olawale Ajose (Head of Access, Neglected Tropical Diseases, DNDi)
Margo Warren (Government Engagement & Policy Manager, Access to Medicine Foundation)
Dr Pauline Beattie (Operations Manager, EDCTP)
10.15-11.45 UTC
Putting access at the centre of future drug development
Margo Warren (Government Engagement & Policy Manager, Access to Medicine Foundation)
Dr Isaac Chikwanha (Senior Director: Investment Strategy, Access & Delivery, GHIT Fund)
Dr Olawale Ajose (Head of Access, Neglected Tropical Diseases, DNDi)
Mathias Duck (Chair of the ILEP Panel of Persons Affected by Leprosy)
11.50-13.10 UTC
Focus: snakebite & snakebite envenoming
Research to address the disease burden of tropical snakebite: challenges and progress
Chair: Prof Robert Harrison (Liverpool School of Tropical Medicine, Centre for Snakebite Research & Interventions)
Dr Cecilia Ngari, Dr Frank Tianyi, Dr Devin Sok, Dr Rachel Clare (African Snakebite Research Group / Scientific Research Partnership for Neglected Tropical Snakebite / CSRI)
13.15-14.45 UTC
COVID19, neglected tropical diseases and repurposing
COVID, NTDs and repurposing: what are the questions, or lessons so far?
Dr Nathalie Strub-Wourgaft (Director of Neglected Tropical Diseases, DNDi)
CURE ID and the CURE Drug Repurposing Collaboratory's (CDRC) Role in Drug Repurposing for NTDs and COVID-19
Heather Stone (Health Science Policy Analyst, US Food & Drug Administration)
Ivermectin and COVID: what's going on?
Dr Carlos Chaccour (BOHEMIA Chief Scientific Officer, ISGlobal)
When secretomes meet anthelmintics: lessons for therapeutic interventions
Dr Lucienne Tritten (University of Zurich)
Drug repurposing for controlling vectorial transmission of Neglected Tropical Diseases
Dr Alvaro Acosta-Serrano (Liverpool School of Tropical Medicine) & Dr Laith Yakob (London School of Hygiene & Tropical Medicine)
15.00-16.30 UTC
Focus: leishmaniasis
Visceral leishmaniasis: the discovery & clinical landscape
Prof Maria Paola Costi (Drug Discovery and Biotechnology Lab, University of Modena and Reggio Emilia, UNIMORE)
Current and future perspectives for the development of new treatments for visceral leishmaniasis
Dr Fabiana Alves (Head of Visceral Leishmaniasis Clinical Programme, DNDi)
Cutaneous leishmaniasis: from bench to cure
Dr Byron Arana (Head of Cutaneous Leishmaniasis, DNDi)
Topical treatments for cutaneous leishmaniasis
Prof Dolores Carrer (Biophysics and Nanotechnology Lab, INIMEC-CONICET-UNC, Argentina)
Biophysical characterization and integrated MD simulation studies of Trypanothione Reductase in Leishmania major
Anurag Kumar (Computational & Systems Biology Lab, National Centre For Cell Science, Pune, Maharashtra, India)
DIAGNOSTICS FOR NEGLECTED TROPICAL DISEASES
ISNTD d3 2021: DAY 2
25 FEB 2021
9.15-10.45 UTC
Essential diagnostics for neglected tropical diseases: from technology to access, for disease elimination
Launch of the World Health Organisation's third Essential Diagnostics List
Dr Francis Moussy (Secretary, SAGE IVD and Essential Diagnostic List, World Health Organisation)
Access to visceral leishmaniasis diagnostics and impact towards attaining the elimination targets in Kenya
Dr Dziedzom Komi de Souza (Senior Scientific Officer, NTD programme, Foundation for Innovative New Diagnostics, FIND)
Focus: schistosomiasis
Reconciling egg- and antigen-based estimates of Schistosoma mansoni clearance and reinfection; a modelling study
Dr Jessica Clark (University of Glasgow)
Schistosoma eggs, circulating antigens or DNA? What do these different diagnostic markers reveal when monitoring praziquantel treatment in a clinical trial?
Dr Pytsje Hoekstra (Leiden University Medical Center, the Netherlands)
10.50-12.20 UTC
Diagnostics innovation for tropical diseases
CRISPR-Cas9-based Point-of-care (PoC) diagnostics for infectious diseases in resource-limited settings
Dr. Mitasha Bharadwaj (Delft University of Technology, Kavli Institute of Nanoscience Delft, Department of Bionanoscience)
Pulse-controlled-amplification: a new powerful tool for on-site diagnostics
Dr Katharina Müller (Institut für Mikrobiologie der Bundeswehr, Germany)
LAMP for Mycobacterium bovis & neglected disease diagnostics
Dr Thoko Flav Kapalamula (Hokkaido University, Japan)
Minimally invasive sampling for Cutaneous Leishmaniasis diagnosis using a microbiopsy device
Saskia Van Henten (ITM Antwerp)
A lab-on-chip system to detect malaria
Kenny Malpartida Cardenas (Department of Electrical and Electronic Engineering, Imperial College London)
12.30-14.00 UTC
Diagnostics gaps for vector-borne diseases & the challenges of febrile illnesses
Diagnostic gaps and challenges for primary healthcare delivery in resource-poor settings
Dr Prudence Hamade (Malaria Consortium)
Digital diagnostics for Africa: more than filling the gap
Dr Aubrey Cunnington (Department of Infectious Disease, Imperial College London)
Multiplex panels for the accurate diagnosis of nonmalarial febrile illnesses
Dr Samuel Duodu (West African Centre for Cell Biology of Infectious Pathogens, University of Ghana)
Novel biomarkers to distinguish between causes of febrile illness
Dr Myrsini Kaforou (Department of Infectious Disease, Imperial College London)
Development of rapid diagnostic tests for arboviruses and viral haemorrhagic fevers
Dr Joseph Fitchett (Centre for Advanced Rapid Diagnostics, Mologic)
14.15-15.45 UTC
Diagnostics beyond diagnosis: evaluation, surveillance & monitoring
Rethinking neglected tropical disease diagnostics to achieve elimination
Katie Gass (Director of Research, The Task Force for Global Health, Neglected Tropical Diseases Support Center, NTD-SC)
Why we need the next generation of point of care tests
Dr Francis Krampa (West African Centre for Cell Biology of Infectious Pathogens, University of Ghana)
Genomic-informed pathogen surveillance in Africa: opportunities and challenges
Dr Seth Inzaule (Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia)
The need for better diagnostics for environmental pathogen detection
Dr Anthony Sifuna (Masinde Muliro University of Science and Technology, Kenya)
Value and application of data from digital diagnostics
Darlington Akogo (Director of minoHealth AI Labs, Ghana)
